Authors
Latest:
Emerging Treatment Landscape and Future Outlook for Friedreich AtaxiaAn expert discusses how vatiquinone targets Friedreich ataxia in patients with balance issues by inhibiting 15-lipoxygenase to reduce oxidative stress. Novel dual-route gene therapy combines systemic IV and targeted dentate nuclei delivery, addressing both central and peripheral manifestations while potentially offering disease-modifying benefits.
Latest:
Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhDThe executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]
Latest:
Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MScThe pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Latest:
Lifestyle Change for Migraine Management: Practical Tips for the Neurologist and PCP, Part 2Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.
Latest:
Current and Future Landscape of Alzheimer Disease Treatment: Emergence of Disease Modifying TherapiesAfter years of failed drug development, the thoughts of disease-modifying therapies for Alzheimer disease are starting to become real.
Latest:
From Fibrosis to Function: Exploring New Pathways in Muscular Dystrophy ResearchNeuromuscular expert Matthew Alexander, PhD, explores the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.
Latest:
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MSAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
Latest:
Managing MS in MillennialsEffectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.
Latest:
Future Directions on Understanding the Link Between Wildfire Particulates and Dementia: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPHA duo of experts highlighted the need for further studies on the exploration of how exposure to wildfire particulate matter impacts neurodegenerative diseases. [WATCH TIME: 2 minutes]
Latest:
Clinical Pearls for CIDP ManagementPanelists discuss how physicians can improve outcomes for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) by prioritizing early and accurate diagnosis, personalizing treatment plans, regularly monitoring patients, and addressing the psychological and emotional impact of the disease.
Latest:
Leah Croll, MD: Importance of Mental Health of Clinicians During COVID-19 PandemicThe neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic.
Latest:
Microglia’s Role in MS and Other Neurodegenerative Diseases: Daniel Reich, MD, PhDThe senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about new opportunities for research into brain lesions and microglia.
Latest:
Switching MG Treatment Due to Adverse Events or Poor Disease ControlExpert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.
Latest:
Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds: Kevin Church, PhDThe chief scientific officer at Athira talked about the potential of hepatocyte growth factor compounds in promoting neurotrophic signaling and providing broad neuroprotection across neurodegenerative diseases. [WATCH TIME: 6 minutes]
Latest:
Gene Therapy, Innovative Drugs, Surgical Techniques, and the Evolving Landscape of Epilepsy Care: Gregory Krauss, MDThe professor of neurology at Johns Hopkins University School of Medicine talked about the need for education to optimize treatment selection and the continually changing landscape of care for patients with epilepsy. [WATCH TIME: 5 minutes]
Latest:
Sharing Treatment Strategies for Patients With Parkinson Disease Beyond Medication: Esther Labib-Kiyarash, MSHA, CPHQAt ATMRD 2025, a patient advocate living with PD and advisory board member of the Parkinson's Foundation outlined key nonpharmacologic tools that have supported her care journey. [WATCH TIME: 5 minutes]
Latest:
Expanded Research on Targeting Mechanisms of Parkinson Disease: Rodolfo Savica, MD, PhDThe consultant in the Department of Neurology at Mayo Clinic discussed the mechanisms of action researchers should key in on for patients with Parkinson disease.
Latest:
Advice for Managing Dravet Syndrome and LGSMary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.
Latest:
Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DOThe vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]
Latest:
Human Endogenous Retroviruses and Their Role in ALS: Avindra Nath, MDThe clinical director of the National Institute of Neurological Disorders and Stroke provided context on two recent papers that highlight a reactivation of HERV-K virus in the development of amyotrophic lateral sclerosis. [WATCH TIME: 5 minutes]
Latest:
Challenges and Opportunities Bringing Lecanemab to Neurology Community ClinicsA group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
Latest:
Need for Improved Access to and Interventions for Mental Health in Multiple Sclerosis: Louise Palmer, MAThe health research assistant at the Shepherd Center discussed the importance of interventions that address mental health for patients with multiple sclerosis, including counseling and support groups. [WATCH TIME: 2 minutes]
Latest:
Differences Between Progressive and Relapsing MS: Benjamin Segal, MDThe chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed the takeaways from his lecture at ACTRIMS Forum 2021.
Latest:
Takeaways, Highlights From the Institutional Perspectives in Neurology: MS: Eric Klawiter, MD, MScThe director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]
Latest:
AUPN 2022 Veterans Health Administration WorkshopGlenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
Latest:
Addressing Treatment Gaps in Adolescents With Myasthenia Gravis: Jonathan Strober, MDThe director of the Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital provided insight on promising data from the phase 2/3 VIBRANCE-MG study assessing investigational nipocalimab in adolesents with myasthenia gravis. [WATCH TIME: 3 minutes]
Latest:
Reviewing Evidence-Based Rehabilitation for Voice and Movement in Parkinson Disease CareCynthia Fox, PhD, CCC-SLP, CEO and co-founder of LSVT Global, discussed the evolution of rehabilitative therapies in PD and stressed early referrals for speech, physical, and occupational therapy.
Latest:
New AASM Guideline, Improved Awareness of Sleep Disorders: Lynn Marie Trotti, MD, MScThe professor of neurology at Emory University School of Medicine spoke on the potential for the new AASM hypersomnolence guideline to educate providers treating patients with sleep disorders.
Latest:
Promising Efficacy of Teriflunomide in Radiologically Isolated Syndrome: Christine Lebrun-Frenay, MD, PhD, FAANThe head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]
